<DOC>
	<DOC>NCT00104078</DOC>
	<brief_summary>The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.</brief_summary>
	<brief_title>Study Evaluating MYO-029 in Adult Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
	<mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
	<criteria>Written informed consent. Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or LimbGirdle Muscular Dystrophy (LGMD) Independently ambulatory Patients with certain clinical conditions Patients using steroids or other medications with the potential to affect muscle function History of sensitivity to monoclonal antibodies or protein pharmaceuticals Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>